Whalesbook
Nuvama analysts report a strong Q2FY26 for India's pharma sector, driven by robust domestic demand and thriving contract manufacturing (CDMO) businesses. Companies like Neuland Laboratories, Lupin, IPCA, and Divi’s Laboratories posted excellent results. However, US generics face significant margin pressure, particularly from gRevlimid erosion. Analysts recommend focusing on domestic and CDMO players for future growth.